MNPR Insider Trading Activity and SEC Form 4 Filings
MNPR insider trading summary
Over the past 12 months, insiders at Monopar Therapeutics (MNPR) reported 36 sales worth $5.7M by 6 insiders and no open-market purchases on SEC Form 4. Net insider selling was $5.7M.
Latest MNPR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 4, 2026 | Kim R Tsuchimoto | Director | Sell | $92K (1,295 @ $70.75) |
| Nov 4, 2026 | Kim R Tsuchimoto | Director | Sell | $43K (600 @ $72.21) |
| Nov 4, 2026 | Kim R Tsuchimoto | Director | Sell | $71K (996 @ $71.35) |
| Nov 2, 2026 | Raymond Anderson | Director | Sell | $56K (840 @ $66.16) |
| Nov 2, 2026 | Raymond Anderson | Director | Sell | $14K (200 @ $68.68) |
| Nov 2, 2026 | Kim R Tsuchimoto | Director | Sell | $84K (1,199 @ $70.10) |
| Nov 2, 2026 | Raymond Anderson | Director | Sell | $40K (600 @ $67.06) |
| Nov 2, 2026 | Raymond Anderson | Director | Sell | $105K (1,502 @ $70.04) |
| Oct 1, 2026 | Christopher M Starr | Director | Sell | $64K (799 @ $79.67) |
| Oct 1, 2026 | Christopher M Starr | Director | Sell | $362K (4,631 @ $78.09) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.